Select a community
Mood Conditions including Depression, Anxiety, Bipolar, OCD, and PTSD
Find out more about the PatientsLikeMe
Mood Conditions Community
Home > Community Treatment Reports > Excedrin Migraine Treatment Report
What is Excedrin Migraine?

Excedrin Migraine is a tablet containing acetaminophen (paracetomol), aspirin, and caffeine. It is an over-the-counter drug used in the treatment of migraine headaches. Excedrein is a brand name owned by Novartis. Read more...Click to read more below

Novartis's Excedrin Migraine site

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken # of patients Major Moderate Slight None Can’t tell # of patients evaluated by
Headaches 10 4
Migraine 5 1
Tension Headaches 2 0
Lower back pain 1 1
Muscle soreness 1 1

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
0 0%
Moderate
1 25%
Mild
0 0%
None
3 75%

Most commonly reported side effects

Must take with food or I will get acid reflux and this stuff tastes nasty!
1 25%
stomach irritation
1 25%
  • Mild
  • Moderate
  • Severe

Dosages

  2 250mg-250mg-65mg as needed 250 mg-250 mg-65 mg as needed 250mg-250mg-65mg as needed 250mg as needed 2 x 250 mg-250 mg-65 mg as needed 3 250mg-250mg-65mg as needed 2 x 250 mg-250 mg-65 mg daily
  9 Number of Patients: 9 2 Number of Patients: 2 5 Number of Patients: 5 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1  

Currently Taking Excedrin Migraine

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
1
0
2
1
1

Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Always
2 50%
Usually
2 50%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
0 0%
A little
1 25%
Not at all
3 75%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
4 100%

See more information, including instructions, precautions, side effects, and interactions.

Report created on November 23, 2009.